Danish pharmaceutical company ALK has secured exclusive global rights to ARS Pharmaceuticals’ Neffy nasal spray, except in select markets, for the treatment of allergic reactions, including anaphylaxis. The deal, valued at over $465 million, positions ALK for significant growth in the anaphylaxis market, with Neffy poised to become a key player in Europe and Canada.
The FDA has approved Neffy, a nasal spray formulation of epinephrine, offering a needle-free option for treating life-threatening allergic reactions known as anaphylaxis. This new treatment provides a convenient and accessible alternative to traditional injectable epinephrine, potentially improving access to rapid treatment and reducing barriers for patients.
